Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 15/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.51 |
| ▸ | AR | P10275 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA3 | P07451 | 4/20 | 0.42 |
| ▸ | CA6 | P23280 | 4/20 | 0.42 |
| ▸ | CA7 | P43166 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.42 |
| ▸ | CA4 | P22748 | 3/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | VDR | P11473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5972458 | 0.91 | ESR1 (0.50) | ESR1ESR2ARCA12CA2 | |
| SCHEMBL3849821 | 0.78 | ESR1 (0.46) | ESR1ESR2ARCA12CA2 | |
| SCHEMBL3856057 | 0.78 | ESR1 (0.50) | ESR1ESR2ARCA12CA2 | |
| SCHEMBL3850228 | 0.78 | VDR (0.61) | ARVDR | |
| SCHEMBL13741489 | 0.71 | ESR1 (0.49) | ESR1ESR2ARCA12CA2 | |
| SCHEMBL4630973 | 0.71 | ESR1 (0.57) | ESR1ESR2ARVDR | |
| SCHEMBL30058620 | 0.71 | ESR1 (1.00) | ESR1ESR2ARVDR | |
| SCHEMBL837374 | 0.71 | ESR1 (1.00) | ESR1ESR2ARVDR | |
| SCHEMBL3853421 | 0.71 | ESR1 (0.52) | ESR1ESR2ARCA12CA2 | |
| SCHEMBL3850788 | 0.71 | MAOB (0.50) | ESR1ESR2ARCA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579488-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579488-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579488-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| EP-1687289-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051938-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106095-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | ESR1 174/4885ESR2 148/4885AR 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.